Jacqualyn A. Fouse's Insider Trades & SAST Disclosures
Jacqualyn A. Fouse's most recent trade in Agios Pharmaceuticals Inc was a trade of 15,933 Common stock done . Disclosure was reported to the exchange on April 8, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jacqualyn A. Fouse.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 15,933 | 156,717 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 15,933 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 08 Apr 2025 | 7,497 | 149,220 (0%) | 0% | 25.9 | 194,172 | Common stock |
| Madrigal Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 1,579 | 1,579 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 894 | 894 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 140,784 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,517 | 12,517 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,830 | 16,808 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 15,934 | 15,933 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 15,934 | 145,187 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Sale of securities on an exchange or to another person at price $ 27.55 per share. | 08 Apr 2024 | 7,791 | 137,396 (0%) | 0% | 27.5 | 214,642 | Common stock |
| Agios Pharmaceuticals Inc | Jacqualyn Fouse A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 23,900 | 0 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Fouse Jacqualyn A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 23,900 | 139,975 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn Fouse A. | Director | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 10,722 | 129,253 (0%) | 0% | 21.6 | 232,024 | Common stock |
| Agios Pharmaceuticals Inc | Fouse Jacqualyn A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,500 | 124,466 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | A. Fouse Jacqualyn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,500 | 0 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | A. Fouse Jacqualyn | Director | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 8,391 | 116,075 (0%) | 0% | 23.0 | 192,909 | Common stock |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 23,900 | 23,900 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 23,900 | 117,684 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 10,718 | 106,966 (0%) | 0% | 28.4 | 303,962 | Common stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,294 | 11,294 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,505 | 13,978 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 15,933 | 98,515 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 15,933 | 31,867 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.35 per share. | 08 Apr 2023 | 4,731 | 93,784 (0%) | 0% | 21.4 | 101,007 | Common stock |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 11,333 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 11,333 | 86,230 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 14 Feb 2023 | 3,648 | 82,582 (0%) | 0% | 28.9 | 105,464 | Common stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 80.32 per share. | 30 Dec 2022 | 252 | 11,473 (0%) | 0% | 80.3 | 20,241 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 66.64 per share. | 30 Sep 2022 | 291 | 11,221 (0%) | 0% | 66.6 | 19,392 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 75.97 per share. | 30 Jun 2022 | 275 | 10,930 (0%) | 0% | 76.0 | 20,892 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,124 | 9,124 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,144 | 10,655 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 170,000 | 170,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 47,800 | 47,800 | - | - | Restricted stock units | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 79.42 per share. | 31 Mar 2022 | 280 | 8,511 (0%) | 0% | 79.4 | 22,238 | Common Stock |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 12,379 | 12,380 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 12,379 | 78,571 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 3,674 | 74,897 (0%) | 0% | 29.1 | 106,840 | Common stock |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 11,334 | 11,333 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 11,334 | 69,697 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 3,505 | 66,192 (0%) | 0% | 30.5 | 106,903 | Common stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 68.78 per share. | 30 Sep 2021 | 271 | 7,942 (0%) | 0% | 68.8 | 18,639 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 84.13 per share. | 30 Jun 2021 | 238 | 7,671 (0%) | 0% | 84.1 | 20,023 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 8,010 | 8,010 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 1,923 | 7,433 (0%) | 0% | 0 | Common Stock | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 81.27 per share. | 31 Mar 2021 | 251 | 5,510 (0%) | 0% | 81.3 | 20,399 | Common Stock |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 11,333 | 61,761 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 11,333 | 22,667 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Feb 2021 | 3,398 | 58,363 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Jacqualyn A. Fouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 163,000 | 163,000 | - | - | Stock option (right to buy) | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 89.74 per share. | 30 Sep 2020 | 219 | 5,022 (0%) | 0% | 89.7 | 19,653 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 103.97 per share. | 30 Jun 2020 | 202 | 4,803 (0%) | 0% | 104.0 | 21,002 | Common Stock |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 10,514 | 10,514 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 1,282 | 4,601 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges